Lacosamida Fresenius Kabi (Lacosamide)

Lacosamide is an antiepileptic agent that modulates neuronal excitability in seizure disorders.

• Partial‑onset seizures: Reduces seizure frequency when added to existing antiepileptic regimens.
• Adjunctive therapy for epilepsy: Improves overall seizure control in patients with refractory focal seizures.
• Focal seizures: Provides additional seizure suppression as part of combination therapy.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes, which stabilizes hyper‑excitable neuronal membranes and diminishes repetitive firing. By selectively targeting the sodium channel's slow inactivation phase, it reduces neuronal hyperexcitability without markedly affecting normal conduction, contributing to seizure control in epilepsy.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dizziness: A sensation of light‑headedness or unsteadiness.
• Nausea: Mild to moderate upset stomach.
• Headache: Pressure or throbbing pain in the head.
• Fatigue: Unusual tiredness or lack of energy.
• Diplopia: Temporary double vision.
• Somnolence: Increased sleepiness during the day.

Serious or Rare Side Effects

• Cardiac conduction abnormalities: Prolongation of PR interval or atrioventricular block.
• Suicidal ideation: Emergence of thoughts of self‑harm.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hypersensitivity: Rash, angioedema, or anaphylactic reactions.
• Respiratory depression: Marked reduction in breathing effort, especially when combined with other CNS depressants.

Before initiating therapy, clinicians should consider several safety aspects related to lacosamide.

• Cardiac monitoring: Obtain baseline ECG and monitor PR interval during treatment.
• Renal impairment: Adjust dose in patients with reduced creatinine clearance.
• Hepatic impairment: Use caution and consider dose modification in severe liver disease.
• Concomitant CNS depressants: Monitor for additive sedation or respiratory depression.
• Pregnancy and lactation: Safety data are limited; weigh potential benefits against unknown risks.
• Store at ambient temperature: Keep in the original container, protect from light and moisture.

Lacosamide can interact with other medicines, influencing its safety or effectiveness.

Major Interactions (Avoid)

• Other sodium‑channel blockers (e.g., carbamazepine, phenytoin): May increase risk of cardiac conduction disturbances.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): Can raise lacosamide plasma concentrations.

Moderate Interactions (Monitor Closely)

• Concomitant anticholinergic agents: May exacerbate cognitive side effects.
• CNS depressants (e.g., opioids, benzodiazepines): May enhance sedation and respiratory depression.
• Diuretics: May affect electrolyte balance, influencing cardiac safety.